news
FDA clears software for Alzheimer's amyloid quantification
The FDA just cleared NeuroQuant, software from Cortechs.ai, that automatically quantifies amyloid plaques on brain scans. This replaces a radiologist's best guess with a standardized number, speeding up Alzheimer's diagnosis and giving doctors a clearer picture of brain aging.
The FDA just cleared NeuroQuant, software from Cortechs.ai, that automatically quantifies amyloid plaques on brain scans. This replaces a radiologist's best guess with a standardized number, speeding up Alzheimer's diagnosis and giving doctors a clearer picture of brain aging.
The architecture take
For years, spotting Alzheimer's amyloid meant a radiologist squinting at a PET scan and making a call based on training. This FDA clearance for NeuroQuant is a big deal because it takes that judgment out of the equation. Now, a machine churns out a hard number, giving a consistent, objective measure of amyloid plaque load. This isn't just about faster diagnosis; it's about pushing the needle toward quantifiable, reproducible biomarkers in brain health. What I'm watching for is how this changes early intervention strategies, especially for those worried about cognitive decline but not yet showing full symptoms. It's a stepping stone toward precision medicine for brain aging, where instead of waiting for memory loss, you get a number to track. That's a different way to think about longevity.